Skip to main content
[Preprint]. 2021 Sep 15:2021.09.11.21263211. [Version 1] doi: 10.1101/2021.09.11.21263211

Figure 2. Vaccine response of CD4 and CD8 T-cells in subjects with IBD.

Figure 2.

Panel A shows the individual absolute CD4 count at baseline and after the first and second dose of the vaccine, identified with the specific biologic being used. Five subjects were on infliximab, 5 on adalimumab, 5 on ustekinumab, 3 on vedolizumab and 1 on azathioprine. There is a mild increase in mean CD4 count after the second vaccine dose. Panel B shows the same parameters for the individual total CD8 counts. There is a small progressive increase in mean CD8 counts after each vaccine dose. These findings suggest the vaccine is safe and do not support a negative effect of vaccination in the cellular response of subjects with IBD receiving biologic/immunomodulatory therapy. Statistical significance was determined by One-way ANOVA multiple comparisons to test for increase or decrease among samples. Tukey’s multiple comparisons test was performed as post-hoc test p<0.05 was considered significant. IBD= Inflammatory Bowel Disease, USTE = ustekinumab, VEDO= vedolizumab, ADA = adalimumab, IFX = infliximab, AZA = azathioprine.